Revive Therapeutics Sees Research Partnership On Psilocybin Expanded

Revive Therapeutics (CSE: RVV) has expanded its sponsored research partnership agreement with that of the University of Wisconsin-Madison related to the study of psilocybin. The partnership will see Revive and the University evaluate novel formulations and a phase 1 clinical study for the therapeutic application of psilocybin for an addiction use disorder.

Development work conducted by the two parties will be focused on tannin-chitosan composites that take the form of thin films, 3D foams and hydrogels. Included research will be physio-chemical characterization, rate of release of psilocybin from composites and the development of composite formulations. The resulting formulations are to be investigated through both pre-clinical and clinical studies against various diseases and disorders.

Tannin-chitosan thin films have been identified by Revive as the lead candidate for a unique delivery film for 1-20mg therapeutic doses of psilocybin.

"As part of our psychedelic-based pharmaceutical strategy, we are focused on balancing research and development of novel psilocybin-based formulations and clinical research of psilocybin to create a robust product pipeline backed by intellectual property and clinical data with the aim to pursue the FDA regulatory pathway for commercialization. Revive plans to expand its clinical development pipeline with psilocybin for various addiction and dependence disorders."

Additionally, Revive Therapeutics also intends to finalize a sponsorship program for a phase 1 study. The study will be focused on examining psilocybin for the treatment of an as of yet undisclosed addiction use disorder. The study will again be conducted by the University of Wisconsin-Madison.

Revive Therapeutics last traded at $0.22 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Revive Therapeutics Adds Turkish Subjects To Bucillamine Phase 3 Clinical Trial For COVID-19

Revive Therapeutics (CSE: RVV) announced on Wednesday that it has expanded its phase 3 clinical...

Thursday, December 30, 2021, 12:49:00 PM

Revive Therapeutics Includes Treating Omicron Variant In Bucillamine Research

Revive Therapeutics (CSE: RVV) announced today that it is expanding its research on oral drug Bucillamine....

Friday, December 3, 2021, 02:56:00 PM

Shroom Boom! Has Michael Frank Brought Revive Back from the Dead?

Yesterday Revive Therapeutics (CSE: RVV) increased 81.8% from 5.5c to 10c on 4.1M shares traded....

Thursday, March 5, 2020, 08:46:25 AM

Revive Therapeutics Announces Research Collaboration For Natural Psilocybin Biosynthesis

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a sponsored research...

Thursday, January 14, 2021, 08:52:49 AM

Revive Therapeutics Announces Final Stages In Bucillamine Phase 3 Clinical Trial For COVID-19

Revive Therapeutics (CSE: RVV) provided on Tuesday updates regarding the phase 3 clinical trial for oral...

Wednesday, January 19, 2022, 09:28:00 AM